Orig3n, Inc., a Boston, MA-based biotechnology company developing treatments for rare and genetically inherited diseases, closed a $12.5m Series A financing.
The round was co-led by Hatteras Venture Partners and Syno Capital with participation from new investor DEFTA Partners and existing investors Harris & Harris Group, Inc., LabCorp, MGC Venture Partners, KTB-KORUS Fund.
The company will use the funds to launch LifeSystems™ cellular models created from its LifeCapsule™ bio-repository.
Founded in 2014 by Robin Y. Smith, CEO, Orig3n is a biotechnology company developing a disease-modeling platform targeting rare genetically inherited diseases. By advancing screening projects using iPSC-derived differentiated cells and delivering the resulting data to inform therapeutic decisions, the company’s platform will replace trial and error guess work of treating disease.
Orig3n recently launched the LifeCapsule bio-repository, a living database of humanity and a large bank of induced pluripotent stem cells, to which anyone can contribute.